CERC stock forecast
Our latest prediction for Cerecor Inc's stock price was made on the Aug. 18, 2021 when the stock price was at 2.78$.
In the short term (2weeks), CERC's stock price should outperform the market by 2.50%. During that period the price should oscillate between -10.23% and +13.85%.
In the medium term (3months), CERC's stock price should underperform the market by -8.15%. During that period the price should oscillate between -47.14% and +31.80%.Get email alerts
Create a solid portfolio with CERC
About Cerecor Inc
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -0.84$ per share.
The book value per share is 0.55$
Three months stock forecastAug. 18, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|